It is estimated that the global mobile health market will be worth $23bn in 2017(1), and it is growing fast: by 2020 it will be worth $61bn(2). Concepta is a key player in this emerging segment having developed a product that focuses on “unexplained infertility” and helping women who suffer from it to conceive.
In just three years, the company has been able to develop an innovative testing platform, obtain product registration and - following a successful listing on the Alternative Investment Market (AIM) on 26th July - is now ready to start commercialisation.
A substantial minority of women struggle to conceive despite many months of trying. And, if doctors cannot find anything physically wrong, these women are usually faced with lengthy periods of worry, insecurity and anxiety. Because they are not typically offered medical assistance until at least a year of trying for a baby unsuccessfully, and aren’t offered IVF until two years have passed, there is a significant period in which these women may feel they aren’t taking enough proactive steps to conceive.
Concepta’s flagship product, MyLotus, measures common issues that can affect a woman’s probability of conception in any given cycle. These issues can vary from cycle to cycle, and when properly accounted for, can reduce the time taken to conceive whereno cause of infertility has been previously identified. MyLotus provides quantitative as well as qualitative results, which is unique for a home fertility test of this kind.
Excitingly, this is only one of many potential future applications for Concepta’s platform. Pharmaceutical companies could use the technology to more effectively monitor patients administering drugs at home – this would be particularly useful as part of clinical trials or to ensure that dosages can be more finely tailored to individual tolerances and requirements.
Likewise, government healthcare representatives should see the value in using this kind of technology to reduce healthcare reliance and hospital admissions by encouraging better health at home. Indeed, indications suggest that in 2017, mobile health could save a total €99bn in healthcare costs in the EU.(3)
The fundamental issues that the Company’s products address are universal and the consumer proposition is unique. Further, a modular manufacturing set-up means flexibility for future applications. Britain’s vote to leave the European Union briefly cast some doubt over the timing of the Company’s float, however this concern was unwarranted and the share issue was oversubscribed. Concepta is at the forefront of a huge growth market within consumer healthcare, and through its clear route to market and the potential for its technology, the investment case is clear to see.
Cambridge Network Limited is a company registered in England under company No. 3400152 The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT
It should be a fun QTR for sure, GLA. I will keep an eye out for updates/articles and post on here. Strong day for buys yesterday (although I never trust the buy/sell chart as can be very subjective/miss leading - not that I don't trust the MMs ...). Stick to the facts and logic - solid plan, milestones being methodically ticked off
The women’s infertility treatment group Concepta plc (AIM:CPT) has announced it's signed a 10 year lease for its new manufacturing facility in Doncaster, Yorkshire.
CEO Erik Henau tells Proactive: ''Opening up the manufacturing facility is preparing us for the big launch [of myLotus]. We have announced in the past that we're near commercialisation with our first market being China so opening up the facility is preparing us for growth''.
Henau said they've also appointed Kevin Su Wei as their China Country Manager, based in Shanghai
Everything looks to be on track still which is very positive. Personally I am looking at March as the really exciting month for this SP, if we can continue to see small rises until then then I am happy. Everyone loves a BLUE day hey. IMO if the product is high quality and delivers results then this will take off in China, which should make UK/EU entry easier providing we pass the QA and regulations. What I like about CPT is they clearly have a solid plan and they are sticking to it. All IMO. GLA.
Erik Henau, chief executive officer at UK- based Women’s Healthcare company Concepta (LON:CPT), discusses the ISO13485 accreditation the group received for its myLotus fertility product with Proactive Investors, ahead of targeted commercial launch in the UK and Europe in the second half of this year.
"It is the first step in achieving compliance with the European regulatory requirements," he says. "On the one hand it's a key approval of what we do and how we do it, the consistency in all operations, and quality throughout the organisation, but it is also a requirement if you want to sell medical devices."
"It is really key for an organisation to achieve this, and in the short time since we have gone through the AIM Market which was at the end of July. So it has been a record achievement for our small start-up business," Henau points out.
Agreed! It is a quiet one ... but quietly confident! Hoping for a good year for this SP and company. My take is that if MyLotus takes off then we may become a takeover target for one of the major players. Just IMO. Really wish everyone the best of luck with CPT hopefully its a fun ride ...
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.